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doi:10.101The Effect of Single and Combined Activating Killer
Immunoglobulin-like Receptor Genotypes on
Cytomegalovirus Infection and Immunity after
Hematopoietic Cell Transplantation
John A. Zaia,1 Joel Y. Sun,2 Ghislaine M. Gallez-Hawkins,1 Lia Thao,1 Arisa Oki,2
Simon F. Lacey,3 Andrew Dagis,4 Joycelynne Palmer,4 Don J. Diamond,3
Stephen J. Forman,2 David Senitzer2It has been shown that activating killer Ig-like receptor (aKIR) genes are important for control of cytomeg-
alovirus (CMV) reactivation after hematopoietic cell transplantation (HCT). To date, using the broad classi-
fication of KIR haplotypes A and B, the precise role of individual KIR genes in the control of infection cannot
be discerned. To address this, a consecutive case series of 211 non-T cell-depleted HCT patients all at risk for
CMVwere monitored biweekly for CMVDNA in plasma by quantitative polymerase chain reaction (Q-PCR)
and at intervals for CMV-specific T cell immunity. Comparing patients with CMV reactivation (n 5 152) to
those with no reactivation (n 5 59), the presence of specific aKIR haplotypes in the donor, but not in the
recipient, were associated with protection from CMV reactivation and control of peak plasma CMV DNA
(P\.001). A donor aKIR profile, predictive for low risk of CMV reactivation, contained either aKIR2DS2
and aKIR2DS4 or had$5 aKIR genes. Neither donor nor recipient inhibitory KIR (iKIR) played a role in a pro-
tective effect. CD41- and CD81-specific CMV immunity did not explain reduced CMV infection. The initial
control of CMV infection after HCT is managed by aKIR functions, and donor aKIR haplotypes deserve
further evaluation in donor selection for optimized HCToutcome.
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Natural killer (NK) cells are considered a bridge
between the innate and adaptive immune systems
because of their ability to provide rapid cytotoxic func-
tion similar to that of innate immunocytes (eg, macro-
phages and granulocytes), and because this cytotoxic
function is closely aligned with that of T lymphocytes
(eg, use of interferon-g, granzymes, and perforins) [1].
It has been suggested that the NK cell provides a cyto-
kine milieu that informs and supports the maturation
of the adaptive immune system [2,3]. NK cells destroy1CMV Laboratory in the Department of Virology; 2De-
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6/j.bbmt.2008.11.030cells infected with viruses and other intracellular
pathogens, transformed cells, and allogeneic cells,
and this involves surface receptors, termed activating
and inhibitory killer immunoglobulin-like receptors
(aKIR, iKIR) (for review, see [4-6]).
The iKIR genes encode receptors that recognize
defined specificities for HLA class I molecules and
block further interaction of NK cell with ‘‘self’’ targets
[1,4,7]. The incompatibility of the iKIR haplotypewith
itsHLA class I ligand has been the subject of intense in-
terest in influencing the outcome of allogeneic hemato-
poietic cell transplantation (HCT) with conflicting
results (for review, see [8]). The KIR haplotype of do-
nor and recipient can have beneficial or detrimental ef-
fects on rate of graft-versus-host disease (GVHD),
relapse, and survival after HCT [9-13]. In addition,
iKIRs have been shown to be involved in improved
time to resolution of hepatitis C virus (HCV) infection
[14,15] and reduced susceptibility to HIV infection
[16,17].
In contrast, aKIR receptor-ligand interactions are
poorly understood, but appear to have an important
effect on control of virus infection. It has been sug-
gested that aKIR haplotypes are inversely associated315
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recipients [18,19]. In HCT with matched-sibling do-
nors, the presence ofmore than 1 aKIRgene (haplotype
B) was associated with reduced CMV reactivation [18].
Identity between donor and recipient aKIR genotypes
has been reported to be associated with a lower inci-
dence of CMV reactivation and lower treatment-
related mortality (TRM) [19]. The question of which
donor aKIR genes are important in protection from
CMV infection has not yet been answered.
The KIR haplotype A contains only 1 aKIR gene
(aKIR2DS4), whereas the haplotype B is composed
of both aKIR and iKIR genes [20]. This haplotype
classification is limited in that most previous KIR gen-
otyping methods could not distinguish aKIR2DS4
from its deletion mutant, a nonexpressing mem-
brane-bound receptor variant. More importantly, the
use of the haplotype A and B system does not permit
assessment of the role of particular aKIR receptors in
control of CMV infection.
In this report, to assess the importance of KIR
genotypes in influencing CMV reactivation, the KIR
genotype was evaluated in a large series of HCT recip-
ients and donor pairs, all of whom were at risk for
CMV infection. A detailed KIR genotype containing
both KIR and aKIR was established, and patients
were prospectively followed and analyzed for CMV in-
fection and effects on CMV-specific adaptive immu-
nity during 1 year posttransplant.PATIENTS AND METHODS
Study Patients
A case series of 211 consecutive allogeneic HCT
recipients, transplanted from 2001 to 2006, were fol-
lowed for CMV reactivation 1 year posttransplant.
Based on study eligibility, all HCT recipients were at
risk for CMV reactivation as determined by CMV an-
tibody seropositivity in either the donor or recipient or
both. All subjects, donors, and recipients signed an in-
formed consent for research approved by the City of
Hope (COH) institutional review board. The donor/
recipient KIR profile was assessed prospectively and
haplotype A and B determined accordingly [20]. Pa-
tients were managed by the clinical staff without
knowledge of the KIR profiles, and transplantation
procedures were performed according to Foundation
for the Accreditation of Cellular Therapy-approved
guidelines. Table 1 describes the general demograph-
ics of the study participants in terms of median age,
transplant type, disease diagnosis, myeloablative ver-
sus nonmyeloablative conditioning, pretransplant
CMV serology of donor and recipient, incidence of
acute and chronic GVHD (aGVHD, cGVHD), and
corticosteroid therapy for GVHD.CMV Surveillance
CMV reactivation was monitored by DNA quanti-
tative polymerase chain reaction (Q-PCR) on plasma
collected twice weekly up to 100 days post-HCT.
CMV surveillance was continued at 1- to 2-week inter-
vals in ‘‘high-risk’’ patients based on clinical manage-
ment guidelines at the COH. High-risk patients
included those with persistent lymphopenia, grade ii-
iv GVHD, or those requiring continued immunosup-
pression for anti-GVHD therapy. The Q-PCR was
performed essentially as previously described using
the CMV-gB DNA as amplification product [21] and
had a limit of detection of 200 genome copies per mil-
liliter plasma (gc/mL). In addition to Q-PCR testing
on plasma, all patients had whole blood cultured for
CMV infection on the same blood specimen and using
a shell vial culture method previously described [22].
Preemptive ganciclovir therapy was implemented
based on either 1 CMV positive shell vial culture or
on 2 consecutive positive Q-PCR assays according to
COH guidelines. The applied definition of CMV dis-
ease was that of Ljungman and Paya [23], and all diag-
noses were based on correlation of clinical events and
documentation of CMV in either bronchoalveolar
lavage (BAL) or in tissue biopsies by histology or by
tissue culture. In this study, CMV infection was
defined as evidence showing CMV in any of 3 tests,
namely, blood culture shell vial, plasma Q-PCR, or
CMV disease by histology. Time to CMV reactivation
was defined as the day of first CMV positive Q-PCR,
and the CMV infection was measured quantitatively
by plasma DNA gc/mL.KIR Genotyping
DNA extraction from donor and recipient WBCs
wasperformedusingQiampDNABloodMiniKit (Qia-
gen, Valencia, CA) as previously described [24]. DNA
was quantified using a Genequant II assay (Pharmacia
Biotech, Piscataway, NJ) and adjusted to15 ng/mL. A
multiplex PCR-sequence-specific (PCR-SSP) was per-
formed on DNA samples as previously described [24]
using 28primers in 4multiplexPCR reactions for detec-
tion of 14 functional KIR genes. The thermal cycler was
aGeneAmp9600, and theDNApolymerasewas Ampli-
taqGold (AppliedBiosystems,FosterCity,CA).The as-
says were run with primer combinations, such that
primer combination 1 included iKIR2DL1, iKIR2DL2,
iKIR2DL4, and aKIR2DS3, primer combination 2
included iKIR2DL3, aKIR2DS2, iKIR3DL1, and
aKIR3DS1, primer combination 3 included iKIR2DL5,
aKIR2DS1, and iKIR3DL2, and primer combination 4
included aKIR2DS4n, aKIR2DS4d, and aKIR2DS5.
This method identifies all 14 functional KIR genes in-
cluding the deletionmutant 2DS4d, but not the pseudo-
genes. The amplified samples were run on a 3% agarose
gel for visualization and analysis. Because KIR2DL4,
Table 1. Study Cohort
Total Patients n5211 Group I *n551 Group II *n5115 Group III * n5 45 P-value
Patient Age:
median (range)
43.1 (18.8, 68.8) 44.8 (19.5, 67.6) 42.2 (18.8, 64.8) 41.9 (20.7, 68.8) 0.27a
Donor Age:
median (range)
42.7 (15.2, 71.4) 43.0 (18.4, 64.4) 42.5 (19.0, 71.4) 39.5 (15.2, 60.2) 0.10a
Donor Type
number (%)
Sibling 141 (67%) 39 (76%) 73 (63%) 29 (64%) 0.25a
URD 70 (33%) 12 (24%) 42 (37%) 16 (36%)
Hematopoietic Progenitor
Cell Source: number (%)
Bone Marrow 32 (15%) 3 (6%) 20 (17%) 9 (20%) 0.09a
Peripheral Blood 179 (85%) 48 (94%) 95 (83%) 36 (80%)
Diagnosis: number (%)
Lymphoid Malignancy 82 (39%) 18 (35%) 45 (39%) 19 (42%) 0.22a
Myeloid Malignancy 118 (56%) 30 (59%) 67 (58%) 21 (47%)
Other 11 (5%) 3 (6%) 3 (3%) 5 (11%)
Conditioning Regimen:
number (%)
Myeloablative: 134 (64%) 30 (59%) 75 (65%) 29 (64%) 0.76a
Nonmyeloablative: 77(36%) 21 (41%) 40 (35%) 16 (36%)
CMV Serology: number
unknown 2 0 1 1 0.53
D+/R+ 133 (64%) 33 (65%) 72 (63%) 28 (64%)
D+/R- 25 (12%) 9 (17%) 11 (10%) 5 (11%)
D-/R+ 51 (24%) 9 (17%) 31 (27%) 11 (25%)
Acute GVHD : number (%)
unknown 1 0 1 0 0.97b
None 58 (28%) 14 (27%) 31 (27%) 13 (29%)
Grade i 24 (11) 5 (10%) 14 (12%) 5 (11%)
Grade ii 83 (39%) 23 (45%) 42 (37%) 18 (40%)
Grade iii 37 (18%) 8 (16%) 21 (19%) 8 (18%)
Grade iv 8 (4%) 1 (2%) 6 (5%) 1 (2%)
Chronic GVHD: number (%)
unknown 4 1 2 1 0.94b
None 48 (23%) 12 (24%) 24 (21%) 12 (27%)
Yes: limited 27 (13%) 6 (12%) 16 (14%) 5 (11%)
Extensive 132 (64%) 32(64%) 73 (68%) 27 (61%)
Steroids
none 52 (25%) 15 (29%) 25 (21%) 12 (27%) 0.4b
0<1mg/kg 99 (47%) 19 (37%) 56 (49%) 24 (53%)
>1mg/kg 60 (28%) 17 (33%) 34 (30%) 9 (20%)
Overall survival 0.72 (0.57,0.82) 0.77 (0.68,0.84) 0.84 (0.70,0.92) 0.2c
CMV indicates cytomegalovirus; GVHD, graft-versus-host disease.
*Group I: no 2DS2–no 2DS4; Group II: 2DS2 or 2DS4; Group III: 2DS2 and 2DS4 or > 5aKIR.
aFisher’s exact test/Kruskal-Wallis test.
bPearson Chi-square test.
cLog-rank test.
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recipients, these were not included in the analyses.
Intracellular Cytokine Assay
In addition to CMV surveillance, blood samples
were analyzed for establishment of CMV-specific
adaptive immunity by intracellular cytokine assay
(ICC), using interferon-g (IFN-g) as the marker pro-
tein, at the following times post-HCT: days 40, 90,
120, 150, 180, and 3606 2 weeks. ICC was performed
on T cells as previously described [21] using Brefeldin
A (25 mg/mL; Sigma, St. Louis, MO) to block the re-
lease of IFN-g. After stimulation with either CMV
Ag (Advanced Biotech, Paterson, NJ) (for CD41 lym-
phocytes) and pp65 or IE1 peptides specific for HLA
A*0201 or B*07 or Pepmix for non-HLA*A0201/or
B*07 (JPT Peptide Technologies, Berlin, Germany)(for CD81 lymphocytes), the cells were fixed, permea-
bilized, then stained with antihuman CD4, CD8, and
IFN-g antibodies. Fluorescein-activated cell sorter
(FACS) analyses were performed using a FACSCanto
flow cytometer (Beckton-Dickinson Biosciences, San
Jose, CA) and data were analyzed using FCS Express
software (version3.0; Denovo Software).
Statistics
The GraphPad Prism 4 software (GraphPad
Software Inc., La Jolla, CA) (www.graphpad.com)
was used for the analysis of CMV DNA Q-PCR re-
sults. Other analyses were performed using the SAS
statistical package and programming language (SAS
Institute Inc., Cary, NC). Contingency tables of num-
bers of patients experiencing CMV reactivation after
HCT were analyzed using Pearson’s chi-square test,
318 Biol Blood Marrow Transplant 15:315-325, 2009J. A. Zaia et al.Fisher’s exact test, and Mantel-Haenszel’s test for or-
dered categories. The Kruskal-Wallis test was used
as a nonparametric analog to 1-way analysis of vari-
ance. Tests were 2-sided and the cutoff for statistical
significance was .05. Survival outcomes were calcu-
lated as time in day’s post-HCT until event or last con-
tact. Kaplan-Meier survival estimates were tested
using theMantel-Haenszel (log-rank) test. Logistic re-
gression analyses were performed to identify indepen-
dent risk factors of CMV reactivation. Cumulative
incidence of first time to CMV-PCR positivity and
peak-PCR among the 3 KIR groups were evaluated us-
ing the last assay date as censored events and relapse or
death as competing risks.RESULTS
KIR Genotype Profile and CMV Reactivation
The KIR genotype profile for donors and recipi-
ents is shown in Figure 1. The donors (Figure 1A)
and the recipients (Figure 1B) were dichotomized,0
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Figure 1. Donor and recipient KIR gene frequency in HCTrecipients with and
to the recipient’s CMV reactivation status (solid columns, n5 152, having at leas
CMV reactivation). The KIR gene frequency is separately portrayed for dono
aKIR2DS4. iKIR2DL4, iKIR3DL2, and iKIR3DL3 were detected in all members
homozygous for KIR haplotype A, and BX indicates individuals either heterozy
using the chi-square test.according to the recipients’ CMV reactivation status,
into either a CMV reactivation group or no-CMV re-
activation group, and the gene frequency is shown for
each group. The aKIR genotypes, aKIR2DS2 and
aKIR2DS4, of donors (Figure 1A), but not of recipi-
ents (Figure 1B), were more frequent in the CMV-
negative group. The donor aKIR2DS2 gene frequency
was 37% in the CMV reactivation group versus 58% in
the no-CMV group (P\ .05 by chi-square test). For
the donor aKIR2DS4, the genotype frequency was
43% in the CMV reactivation group versus 58% in
the no-CMV group (P 5 .06). Importantly, the
aKIR2DS4 deletion mutant (aKIR2DS4d), which
does not express membrane-bound aKIR2DS4, was
found to be more prevalent in donors in the CMV re-
activation group compared to the no-CMVgroup (P#
.05 by a chi-square test). This argues for the impor-
tance of donor aKIR2DS2 and aKIR2DS4 in control
of CMV reactivation in the recipient. Of note, the
iKIR genotype, 2DL2, was also significantly more fre-
quent in the donors in the noninfected group, but
2DL2 iKIR and the aKIR2DS2 aKIR are in strong2D
S4
2D
S4
d
2D
S5
3D
L1
3D
S1 AA BX
No CMV reactivation
without CMV reactivation. The cohort has been dichotomized according
t 1 incident of CMV reactivation; and stripped columns, n5 59, having no
rs (A) and recipients (B). aKIR2DS4d represents the deletion variant of
of this cohort, and thus omitted from this figure. AA indicates individuals
gous (BA) or homozygous (BB) for KIR haplotype B. *P 5 .06, **P # .05
Biol Blood Marrow Transplant 15:315-325, 2009 319Association of Donor aKIRs with Decreased CMV Incidencelinkage disequilibrium and are expected to be ex-
pressed together. In contrast, the iKIR genes, 2DL1,
2DL3, 2DL5, and 3DL1, of both the donors and the
recipients distributed similarly between the 2 groups
with and without CMV reactivation (see 2DL1,
2DL2, 2DL3, 2DL5, and 3DL1 in Figure 1). Finally,
the AA and BX haplotypes did not show any significant
difference in proportions between the CMV reactiva-
tion group and the no-CMV group (39% versus
29%, respectively, for donor haplotype AA and 61%
versus 71%, respectively, for donor haplotype BX).
In summary, in answer to the question of which KIR
genotypes are most frequently associated with protec-
tion from CMV reactivation, donor aKIR2DS4, the
absence of the aKIR2DS4 deletion, and the iKIR
gene 2DL2 that is linked with aKIR2DS2 were most
prevalent.Donor aKIR Profile and CMV Reactivation
Incidence
To further examine the contribution of donor
aKIR genotype to CMV reactivation in the recipient,
CMV reactivation was analyzed based on number of
aKIR genes in the donor. As shown in Figure 2A, the
prevalence of recipients with CMV reactivation was
significantly higher if the number of aKIR genes per
donor was \5. Only 17% of the recipients whose
donors had 0 aKIRs were free of CMV infection
post-HCT; 27% of those with 1-4 aKIRs in the donor
genotype had no CMV infection, and 52% of those
with $5 aKIRs never developed CMV reactivation
(P5 .03 by a chi-square test). These results confirmed
that the protection fromCMV reactivation was associ-
ated with increased numbers of aKIR genes in the do-
nor genotype.
Because of the observation for CMV protection in
the presence of the aKIR2DS2 and aKIR2DS4 genes
in donors, the effect of a single appearance or combina-0  
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Figure 2. CMV reactivation and aKIR profiles. (A) Percent CMV reactivation
aKIR (n5 161) and equal to 5 or more aKIR (n5 20). Chi-square t-test is sign
type of donor aKIR combinations, including No aKIR2DS2 or aKIR2DS4 (n 5
aKIR2DS4 (n 5 36). Chi-square t-test is significant for independence, P 5 .001tion of these 2 genes was also evaluated (see Figure 2B).
As shown, only 18% of the recipients having no
aKIR2DS2 and aKIR2DS4 in their donor cells
remained free of CMV infection; 25% of those with ei-
ther 1 of these genes (aKIR2DS2 or aKIR2DS4) did
not develop CMV infection; and 53% in those with
both aKIR genes remained free of CMV infection.
Thus, the presence of aKIR2DS2 and aKIR2DS4 was
associated with decreased CMV reactivation (P 5
.001 by chi-square test).Characterization of CMV Infection Based on
aKIR Donor Genotype
This formed the basis for a hypothesis that
aKIR2DS2 and aKIR2DS4 genes play the major role
in protection from CMV reactivation. To test this hy-
pothesis, we investigated CMV infection in recipients
whose donors had both of these genes versus those that
did not. Because the data show that the number of do-
nor aKIR ($5) is protective of CMV reactivation as
well as the presence in the donor of both 2DS2 and
2DS4 aKIRs, the donor/recipient pairs were grouped
according to donor aKIR genotype as follows: Group
I had no aKIR2DS2, aKIR2DS4, and\5 aKIR total
genes; Group II had either aKIR2DS2 or aKIR2DS4
and\5 aKIR total genes; Group III had 1 of the pos-
sible combinations of aKIR2DS2 plus aKIR2SD4 and/
or $5 aKIR genes. The CMV reactivation rate for
each group is shown in Table 2, and the difference in
CMV rates, with Group III having the lowest rate,
was statistically significant by chi-square analysis (P
\ .001). In addition, the number of CMV episodes
(as measured by Q-PCR) were significantly lower in
Group III (P 5 .001), with less frequency of both 1
CMV episode (27% inGroup III versus 37% inGroup
II or 43% in Group I) and of 2 CMV episodes (11% in
Group III versus 23% in Group II or 20% in Group I).
So the conclusion can be made that Group IIINo
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.
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and fewer recurrences of CMV infection.
Of note, as shown in Table 2, the median times to
first CMV infection, as detected by Q-PCR or shell
vial assay, was similar in all groups I, II, and III (P 5
.15 and .37, respectively, by Kruskal-Wallis test). For
groups I, II, and III, the plasma Q-PCR became posi-
tive at a median time in days of 37, 50, and 44, respec-
tively, and the shell vial cultures had amedian first time
positive of 47 days for all groups. Although the inci-
dence of disease was not significantly different across
groups because of the small numbers, most disease
occurred in Groups I and II, with 5 cases of CMV
pneumonitis. There was no CMV pneumonitis, and
only 1 case of CMV gastroenteritis in Group III
(P 5 .47 by chi-square test). Therefore, it appeared
that there was a difference in the percentage of recipi-
ents with CMV reactivations for the 3 groups but, if in-
fection was to occur, the time to first reactivation was
not different in Groups I, II, and III (Table 2).
To analyze the kinetics of appearance of CMV
reactivation in these 3 groups after HCT, a cumulative
incidence curve was established plotting the first time
to reach CMV Q-PCR positivity for each subject
(Figure 3A). The subjects with no CMV infection
were censored at the last day of follow-up, with relapse
and death treated as competing risks. As shown, the
occurrence of CMV infection was significantly less in
Group III (P \ .001 by log-rank test). In addition,
the occurrence of first infection went beyond day 100
post-HCT in Groups I and II (150-200 days post-
HCT), whereas CMV reactivation no longer occurred
by day 100 in Group III. In Group III, CMV reactiva-
tion appeared to be controlled, as detected by Q-PCR,
in 53% of the recipients compared to only 14% and
25% of Groups I and II, respectively.Table 2. Donor KIR profile and CMV reactivation
Group I * n551 Group
CMV reactivation
yes 44 (86%) 86 (75
no 7 (14%) 29 (25
CMVepisodes
none 13 (25%) 41 (36
1 22 (43%) 43 (37
2 10 (20%) 26 (23
3 6 (12%) 3 (3%
>3 0 2 (1.6
CMV Infection: median time to first event in days (range)
Q-PCRd 37 (21-356) 50 (22
SV assayd 47 (30-122) 47 (21
CMV Disease: number (%)
CMV pneumonitis 2 (3.9%) 3 (2.6
CMV gastroenterocolitis 4 (7.8%) 5 (4.3
CMV indicates cytomegaovirus; SV, shell vial assay; Q-PCR, quantitative polym
*Group I: no 2DS2–no 2DS4; Group II: 2DS2 or 2DS4; Group III: 2DS2 and 2
aChi-square test.
bChi-square test on episodes 0-3.
cKruskal-Wallis test.
dQ-PCR plasma CMV > 200gc/ml.To check whether the severity of CMV viremia
was different in each group, the proportion reaching
peak CMV DNA plasma level was analyzed using
a similarly censored cumulative incidence plot that
showed a pattern similar to time to first Q-PCR posi-
tivity (see Figure 3B; P\ .001 by log-rank test). To
further characterize the nature of the infection in these
3 groups, the plasma CMV load was expressed as
genome copies/mL plasma (gc/mL) for the first
CMV detection (Figure 3C) or for peak CMV load
(Figure 3D) using a scatter plot that included the
0 gc/mL values for the patients who did not reactivate
CMV. Here again, the median CMV loads at first
detection and at peak level were lowest in group III
(Figure 3C; P \ .001, and Figure 3D, P\ .001 by
Kruskal-Wallis tests). In summary, recipients of
donors having aKIR haplotypes containing aKIR2DS2
and aKIR2DS4 or $5 aKIR genes had proportion-
ately less CMV reactivation and earlier control of in-
fection compared to those with only a single aKIR,
aKIR2DS2, or aKIR2DS4, or\5 aKIR genes.Comparison of Clinical Characteristics among
the aKIR Groups
A comparison of the clinical characteristics among
the aKIR groups was performed to ensure that no
baseline differences existed among these factors (see
Table 1). The comparison was performed using con-
tingency tables, and the characteristics studied were:
donor and recipient age, type of HCT, source of blood
progenitor cells, underlying diagnosis, conditioning
regimen, pre-HCT CMV antibody in donor and
recipient, incidence of aGVHD and cGVHD, and
use of corticosteroid therapy. As shown in Table 1,
the results of this evaluation show that there were noII * n5115 Group III * n545 p value
%) 22 (48%) p < .001a
%) 23 (52%)
%) 28 (62%) .001b
%) 12 (27%)
%) 5 (11%)
) 0
%) 0
-153) 44 (22-87) .15c
-259) 47 (27-76) .37c
%) 0 .47a
%) 1 (2.2%)
erase chain reaction; KIR, killer immunoglobulin- like receptors.
DS4 or > 5aKIR.
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Figure 3. CMV reactivation profile for each Group I, II, and III. (A) Time to first CMV positivity by Q-PCR is shown for subjects in each group (log-rank
test P5.004). (B) Time to peak Q-PCR is shown for subjects in each group (log-rank test P5.015). (C) Amounts of CMV genome copies/mL are shown
at time of first detected CMV reactivation (Kruskal-Wallis test, P5.0001). (D) Peak amounts of CMV genome copies/mL are shown (Kruskal-Wallis test,
P\.0002).
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tics among the aKIR groups. In addition, there were
no differences in the groups with regard to overall sur-
vival (OS) as reported at 3 years post transplant.Logistic Regression Analysis of Factors Affecting
CMV Reactivation
The univariable logistic regression analysis, as
shown in Table 3, examined factors previously shown
to have an impact on CMV reactivation. Among the
variables tested, the most important was the KIR
Risk Groups, Group III being highly significant (P 5
.0003) and other variables such as aGVHD (P 5
.006). In addition, the material transplanted, bone
marrow versus PBSCs (P5 .03), and donor KIR2DS2
(P 5 .01) and donor KIR2DS4 (P 5 .06, borderline)
were also important independent variables in this
model. All other variables such as age of donors or
recipients, related versus unrelated donor type, condi-
tioning intensity, CMV serology of at-risk donor-
recipient pairs, or prednisone dose were not associated
with CMV reactivation. The study excluded donor-
recipient pairs that were CMV seronegative pretrans-
plant, and, therefore, the baseline chosen for the
univariate comparison of CMV serology was D1/R2.
This may explain the lack of significant difference
based on serostatus of donor and recipient. In addition,the prednisone dose was based on the highest dose
given to a recipient, but time to highest dose was not
included in the model (overall P 5 .26).
The multivariable logistic regression analysis of
factors affectingCMVreactivation, as amodel of good-
ness of fit (P 5 .001) included the donor KIR2DS2
genotype, donorKIR2DS4genotype, the combination
donor KIR2DS2 and KIR2DS4 genotypes, aGVHD,
and the transplant source (Table 4). The individual
donor aKIRs were included in this model, and for
this reason the KIR groups I, II, and III, which dupli-
cate the KIR variables, could not be added into the
analysis. However, this model establishes the impor-
tance of donor aKIR2DS2 and aKIR2DS4 genotype
as factors in decreasing the risk of CMV reactivation
in recipients.Adaptive Immune Response within Donor KIR
Groups
The next question was whether the influence of the
donor aKIR genotype on CMV infection was associ-
ated with an enhanced development of CMV-specific
T cell immunity post-HCT. A cumulative incidence
plot was established for recipients monitored prospec-
tively for adaptive immune response by intracellular
cytokine assay (ICC) at days 40, 90, 120, 150, 180,
and 365 post-HCT. The immune responses were
Table 3. Univariable Logistic Regression Affecting the Percentage of CMV Reactivation
Variables N Odds Ratio (95% CI) P-value
Recipient Age at Transplant (continuous) 210 1.00 (0.98, 1.03) 0.85
Donor Age at Transplant (continuous) 210 1.01 (0.98, 1.04) 0.58
Patient Sex
Female 99 (baseline) 0.68
Male 111 0.88 (0.48, 1.61)
Donor Sex
Female 83 (baseline) 0.33
Male 127 1.35 (0.73, 2.50)
Donor Type
Sibling Donor 140 (baseline) 0.83
Matched Unrelated Donor 70 0.93 (0.49, 1.76)
Transplant source
Bone Marrow 32 (baseline) 0.03
Peripheral Blood Stem Cells (PBSCs) 178 2.37 (1.09, 5.15)
Conditioning intensity
Fully Ablative 133 (baseline) 0.69
Non-myeloablative Reduced Intensity 77 1.14 (0.60, 2.15)
Diagnosis 0.98*
Lymphoid Malignancy 81 (baseline) 0.84
Myeloid Malignancy 118 1.07 (0.57, 2.00) 0.94
Other 11 1.06 (0.26, 4.34)
CMV Serology 0.59*
D+/R- 25 (baseline) 0.34
D+/R+ 132 1.56 (0.63, 3.85) 0.34
D-/R+ 51 1.64 (0.59, 4.61)
Acute GVHD II+ (grade II-IV)
No 77 (baseline) 0.006
Yes 122 2.47 (1.30, 4.69)
Chronic GVHD
No 41 (baseline) 0.42
Yes 165 1.36 (0.64, 2.86)
Prednisone Dose 0.26
No Prednisone (0) 41 (baseline)
Low Dose Prednisone (< 1) 104 1.49 (0.69, 3.21) 0.31
High Dose Prednisone (>5 1) 64 2.06 (0.86, 4.91) 0.10
Donor aKIR 0.006*
No KIR2DS2 and no KIR 2DS4 57 (baseline)
KIR2DS4 and no KIR2DS2 64 0.70 (0.28, 1.70) 0.43
KIR2DS2 and no KIR 2DS4 53 0.59 (0.24, 1.48) 0.26
KIR2DS2 and KIR2DS4 35 0.20 (0.08,0.52) 0.0009
KIR Risk Groups 0.0006*
I (No 2DS2 or 2DS4) 51 (baseline)
II (2DS2 or 2DS4 or < 5 aKIR) 115 0.47 (0.19, 1.16) 0.10
III (2DS2 and 2DS4 and /or > 5aKIR) 44 0.16 (0.06, 0.43) 0.0003
CI indicates confidence interval; GVHD graft-versus-host disease; KIR, killer immunoglobulin-like receptor; CMV, cytomegalovirus.
*P-value of the model.
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immunity at 1  106 CD41/IFN-g1 or CD81/IFN-
g1 cells/L when stimulated in vitro with CMV antigen
(CD41 cell assay) or a mixture of overlapping CMV-
pp65 peptides or CMV-IE1 peptides (CD81 cell
assay). The HLA A*0201 and B*07 were stimulated
with pp65 peptides specific to their alleles. As shown
in Figure 4, Group I consistently developed immunity
prior to groups II and III, possibly because of the in-
creased infection rate in this group, but this was signif-
icantly different only for CD8 response to CMV-IE1
(Figure 4B, P 5 .03). CD81 cell reactivity to CMV
pp65 (Figure 4A) and CD41 cell immunity to CMV
antigens (Figure 4C) did not have a significant impact
from the donor aKIR haplotype. Interestingly, the cu-
mulative incidence profile for immune response recov-
ery in all 3 CMV assays were very similar for Group IIand Group III (see Figure 4A-C), suggesting that the
presence of donor aKIR2DS2 and aKIR2DS4 KIR ge-
notype, or $5 donor aKIRs, affected the adaptive re-
sponse in the same fashion.DISCUSSION
NK cells play a vital role in the innate immune
response to viral infections. The mechanism(s) that
control this important protective response are only be-
ginning to be understood. Innate immunity against vi-
ral infections is mediated through NK cells, whose
function is dependent in part upon KIR genes from
the Lymphocyte Receptor Complex on chromosome
19.WhenNK cells have been implicated in HCT out-
comes, for example, survival, relapse, and GVHD, it
Table 4. Multivariable Logistic Regression Affecting the Percentage of CMV Reactivation
Variables N Odds Ratio (95% CI) P-Value
Model goodness of fit 198 .001*
Donor KIR-2DS2 and KIR 2DS4
No KIR2DS2 and no KIR2DS4 53 (baseline)
KIR2DS4 and no KIR2DS2 59 0.87 (0.32, 2.32) .78
KIR2DS2 and no KIR2DS4 52 0.59 (0.22, 1.55) .28
KIR2DS2 and KIR2DS4 34 0.21 (0.08, 0.58) .003
aGVHD II+ (grade II-IV)
No 76 (baseline)
Yes 122 2.64 (1.33, 5.23) .006
Transplant source
Bone marrow 28 (baseline)
Peripheral blood stem cells 170 2.36 (0.97, 5.76) .06
aGVHD indicates acute graft-versus-host disease; CMV, cytomegalovirus; KIR, killer immunoglobulin-like receptor; CI, confidence interval.
*Wald test.
Biol Blood Marrow Transplant 15:315-325, 2009 323Association of Donor aKIRs with Decreased CMV Incidencehas been the iKIR donor and recipient ligand-ligand
compatibility that appeared most important [8,10].
However, the effect of KIR haplotypes on outcome re-
mains controversial with beneficial and detrimental ef-
fects observed depending on whether it was a related
sibling transplant [13] or unrelated transplant [8,25],
whether it was T cell-depleted [10] or T cell replete-
transplant [12], and other aspects such asmyeloid diag-
nosis, use of anti-T cell globulin, and age of patient [8].
It is likely that the variability of the KIR repertoire, the
significant gene polymorphisms, and the variable NK
responses also contribute to these different outcomes
[26,27].0
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acterization of donor and recipient [24], it is possible to
determine the contributions of the various aKIR
genes. Our data indicate that the aKIR genotype of
the donor is important in limiting CMV reactivation,
and that iKIR, in either the donor or recipient, are
not associated with reduction in CMV reactivation.
This allowed the testing of a hypothesis that specific
donor aKIR genotypes had prominence in control of
CMV reactivation. Our data indicate that both
aKIR2DS2 plus aKIR2DS4, in the donor genotype,
are associated with reduced CMV activation in HCT
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324 Biol Blood Marrow Transplant 15:315-325, 2009J. A. Zaia et al.same association was found regardless of which aKIR
genes were present in the donor genotype, as long as
there were at least 5 or more aKIR alleles present. A
protective donor genotype was defined as that in which
there are both aKIR2DS2 and aKIR2DS4 or$5 aKIR
genes. The recipients of HCT from donors with the
beneficial aKIR haplotype had significantly less
CMV reactivation, had no reactivation after day 100,
and had significantly lower median peak CMV load.
More importantly, although not significantly different
because of small numbers, CMV disease was minimal
in this group and no CMV pneumonia occurred.
A complexity of interpretation is introduced when
the broad haplotyping system is used that divides all
patients into haplotypes A and B. Individuals geno-
typed positive for the so-called ‘‘framework genes,’’
plus only an aKIR2DS4 locus, are KIR haplotype A
homozygotes. Those with additional aKIR loci are ei-
ther AB or BB haplotypes and are grouped together as
KIR haplotype B. Therefore, KIR haplotype B carriers
potentially express multiple aKIRs. Yet, the classifica-
tion of haplotype A and B does not define the full com-
plement of aKIR and iKIR genes. Therefore, the
contribution of individual genes to antiviral effects
has not been precisely evaluated. Although this system
has been useful in defining risk for GVHD and for sur-
vival in matched related HCT [13], it does not allow
for evaluation of specific aKIR gene relationships.
The aKIR genes do not appear to play a role in altering
GVHDor relapse after HCT, but they have been asso-
ciated with decreased reactivation of CMV [18,19]. In
the study of Cook et al. [18], it was reported that in T
cell-replete HCT in matched sibling donor trans-
plants, the presence of donor KIR haplotype B was
associated with a 65% reduction in CMV reactivation.
Our results confirmed a small protective effect of hap-
lotype B, but showed amajor protective effect of donor
aKIR genotype aKIR2DS2 and aKIR2DS4.
Chen et al. [19] were the first to characterize the
actual number of donor and recipient KIR genes rela-
tive to CMV infection, but they did not distinguish
between the aKIR2DS4 and its inactive deletion
aKIR2DS4d. In their paper, HCT recipients of a T
cell-replete transplant from HLA identical sibling do-
nors having more aKIR genes were shown to have
lower treatment-related mortality (TRM), better sur-
vival, and a reduced incidence of CMV reactivation.
Our data includes T cell-replete transplant recipients
with unrelated donors and demonstrates that the pro-
tective effect of increased donor aKIR genotypes on
CMV infection extends to this population.
It is important to note, however, that although the
CMV reactivation was significantly less, approximately
half of the recipients with donors having the favorable
donor aKIR genotype still reactivated CMV. CMV
reactivation occurred in 48% of those in the protected
group, and when this occurred, there was no differencein time to first infection or in median CMV plasma
DNA levels. However, significantly fewer episodes of
CMV infection occurred in this group. It is possible
that there is variable expression of aKIR receptors, as
has been shown with iKIR [27], and this could explain
the breakthrough of CMV reactivation despite the
donor aKIR genotype. KIR expression in mice has
been shown to vary with promoter polymorphisms
and epigenetic silencing events [28], and it is possible
that similar variations in expression of aKIR will be
linked to the control of CMV reactivation.
NK cells are not the only cells expressing KIR
receptors, which are also expressed on CD81 T cells
(NKT), and there is evidence that NK cells interact
in support of adaptive immunity [2,6]. Thus, the ques-
tion was raised as to whether the aKIR contribution is
mediated by an enhanced adaptive immune response in
our patients. In the murine CMV (MCMV) model, the
continuum of interaction between innate processes,
involving dendritic cells and NKT cells, produces an
initial interferon (INF)-a response, which appears to
activate NK cells and leads to control of MCMV
[29]. In this model, it has been proposed that the
potential immunosuppressive effect of INF-a is
relieved by the NK-induced reduction of MCMV
infection, and this allows for expansion of MCMV-
specific CD4 and CD8 lymphocytes [30]. Of note, in
themousemodel,NK cells can also limit the expansion
of the CD4/CD8 responses by unknown mechanisms
[31]. In our study, there was no enhancement of the
CD41 or CD81 lymphocyte response to CMV that
would explain the reduced infection in the group
with donor enhanced aKIR haplotype. Neither the
CD4 responses to CMV antigens nor the CD8 re-
sponses to CMV pp65 peptides were different among
the groups with varying donor aKIR genotypes. As
part of a separate study, IFN-g1 CD81 cells from
this same patient cohort were further evaluated for
the expression of simultaneous multiple immunologic
functions using a CMV-pp65 peptide library for in-
duction of MIP-1b, tumor necrosis factor-alpha
(TNF-a), and CD107 degranulation. Similarly, there
was no effect of aKIR donor genotype (W. Zhou, per-
sonal communication). We did observe an association
of the aKIR donor haplotype with significant reduc-
tion in CD81 lymphocyte responses to CMV-IE1
(see Figure 3A and B). It is possible that this is because
of the reduction in CMV infection by aKIR effects, but
the actual mechanism is unknown. Of note, the fact
that reduced CMV infection occurred in the absence
of enhanced CD8-specific immunity, further supports
the overall importance of NK cells, acting by means of
the aKIR receptor-ligand, in initial control of CMV.
These data support the conclusion that both
aKIR2DS2 plus aKIR2DS4, or a total of at least 5
aKIR in the donor KIR haplotype, are associated
with reduced CMV infection in T-replete allogeneic
Biol Blood Marrow Transplant 15:315-325, 2009 325Association of Donor aKIRs with Decreased CMV IncidenceHCT transplantation. Even in those with reactivation
of CMV, the favorable donor haplotype appeared to
exert a better control of the infection. These data bet-
ter define the aKIR contribution to control of CMV in
this population and suggest that donor aKIR genotype
be included in algorithms for optimizing the outcome
of HCT in related and unrelated T cell-replete alloge-
neic donor transplantation. Larger studies will be nec-
essary to determine whether selective consideration of
a donor aKIR repertoire might be of benefit to the suc-
cess of allogeneic transplants.ACKNOWLEDGMENTS
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